Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021

Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021

RANCHO CUCAMONGA, CA – March 10, 2022 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2021.

Fourth Quarter Highlights

Net revenues of $120.9 million for the fourth quarter
GAAP net income of $19.8 million, or $0.39 per share, for the fourth quarter
Adjusted non-GAAP net income of $20.8 million, or $0.42 per share, for the fourth quarter

Full-Year Highlights

Net revenues of $437.8 million for the fiscal year
GAAP net income of $62.1 million, or $1.25 per share, for the fiscal year
Adjusted non-GAAP net income of $68.0 million, or $1.37 per share, for the fiscal year

Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer commented: “Last year was a turning point for Amphastar – with financial strength driven by the continued growth of our higher-margin products. We expect a number of pipeline milestones to be reached in 2022 as we continue to execute the Company’s strategy.”

Three Months Ended

Year Ended

 

December 31, 

December 31, 

 

2021

2020

2021

2020

 

(in thousands, except per share data)

 

Net revenues

    

$

120,887

    

$

95,921

    

$

437,768

    

$

349,846

GAAP net income (loss) attributable to Amphastar

$

19,760

$

(6,273)

$

62,116

$

1,403

Adjusted non-GAAP net income attributable to Amphastar*

$

20,833

$

7,994

$

67,999

$

31,616

GAAP diluted EPS attributable to Amphastar stockholders

$

0.39

$

(0.13)

$

1.25

$

0.03

Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders*

$

0.42

$

0.16

$

1.37

$

0.64


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Thursday, March 10, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Shares
Expense
Product
Geography
Income
Cash Flow
Earnings
Other
Inside Amphastar Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income (Loss)
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Details)
Accounts Payable And Accrued Liabilities (Tables)
Anp Restructuring
Anp Restructuring (Details)
Business
Commitments And Contingencies
Commitments And Contingencies (Future Minimum Rental Payments) (Details)
Commitments And Contingencies (Lease Cash Flow Information) (Details)
Commitments And Contingencies (Lease Expense) (Details)
Commitments And Contingencies (Purchase Commitments) (Details)
Commitments And Contingencies (Tables)
Customer And Supplier Concentration
Customer And Supplier Concentration (Details)
Customer And Supplier Concentration (Tables)
Debt
Debt (Long-Term Debt Maturities) (Details)
Debt (Narrative) (Details)
Debt (Schedule Of Debt) (Details)
Debt (Tables)
Employee Benefits
Employee Benefits (Details)
Fair Value Measurements
Fair Value Measurements (Fair Values Of The Company's Financial Assets And Liabilities) (Details)
Fair Value Measurements (Tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Summary Of Changes In The Carrying Amount Of Goodwill) (Details)
Goodwill And Intangible Assets (Summary Of Expected Amortization Expense) (Details)
Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details)
Goodwill And Intangible Assets (Tables)
Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Stockholders
Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Stockholders (Calculation Of Basic And Diluted Net Income (Loss) Per Share) (Details)
Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Stockholders (Narrative) (Details)
Income Per Share Attributable To Amphastar Pharmaceuticals, Inc. Stockholders (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Reconciliation Of The Statutory Federal Income Tax Rate To The Effective Tax Rate) (Details)
Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details)
Income Taxes (Schedule Of Deferred Tax Assets/Liabilities) (Details)
Income Taxes (Summary Of Income (Loss) Before Income Taxes) (Details)
Income Taxes (Summary Of Provision (Benefit) For Income Taxes) (Details)
Income Taxes (Tables)
Income Taxes (Uncertain Income Tax Positions - Narrative) (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Investments
Investments (Equity Method Investment) (Details)
Investments (Held-To_Maturity) (Details)
Investments (Tables)
Litigation
Litigation (Details)
Property, Plant, And Equipment
Property, Plant, And Equipment (Narrative) (Details)
Property, Plant, And Equipment (Summary Of Property, Plant, And Equipment) (Details)
Property, Plant, And Equipment (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Revenue Recognition
Revenue Recognition (Analysis Of Product Return Liability) (Details)
Revenue Recognition (Analysis Of The Chargeback Provision) (Details)
Revenue Recognition (Tables)
Segment Reporting
Segment Reporting (Depreciation And Amortization Expense By Reporting Segment) (Details)
Segment Reporting (Selected Financial Information By Reporting Segment) (Details)
Segment Reporting (Summary Of Net Revenues By Product Segment) (Details)
Segment Reporting (Summary Of Revenues And Long-Lived Assets By Geographic Region) (Details)
Segment Reporting (Tables)
Stockholders' Equity
Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)
Stockholders' Equity (Common And Preferred Stock) (Details)
Stockholders' Equity (Information Relating To Option Grants And Exercises) (Details)
Stockholders' Equity (Information Relating To Rsu Grants And Deliveries) (Details)
Stockholders' Equity (Key Assumptions Used In Determining Fair Value Of Options Granted) (Details)
Stockholders' Equity (Restricted Stock Units) (Details)
Stockholders' Equity (Share Buyback Program) (Details)
Stockholders' Equity (Share-Based Compensation Expense Included In The Statement Of Operations) (Details)
Stockholders' Equity (Summary Of Nonvested Options) (Details)
Stockholders' Equity (Summary Of Option Activity) (Details)
Stockholders' Equity (Tables)
Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)
Stockholders' Equity (The 2018 Anp Equity Incentive Plan) (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Schedule Of Intangible Useful Lives) (Details)
Summary Of Significant Accounting Policies (Schedule Of Pp&Amp;E Useful Lives) (Details)
Summary Of Significant Accounting Policies (Tables)
Ticker: AMPH
CIK: 1297184
Form Type: 10-K Annual Report
Accession Number: 0001297184-22-000007
Submitted to the SEC: Fri Mar 11 2022 4:13:54 PM EST
Accepted by the SEC: Fri Mar 11 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-22-000007.htm